Skip to main content
Menu

Posts tagged with "Clinical Trials"

  • Clinical Trials

    An Awful Idea: Paying to Get Into a Clinical Trial

    This article at Stat by Rebecca Robbins really caught me eye. It describes clinical trials where the participants are being asked to pay thousands of dollars just to join the trial. There seems to have been an increase in this sort of thing lately, and I’ll be completely clear: I think that’s a terrible idea… Read More
  • Analytical Chemistry

    Acronym Fever. We Need an Acronym For That.

    The Wall Street Journal published a provocative article the other day, entitled “Don’t Understand Moronic Bromides?” about the proliferation over the years of acronyms in science.(Note the old-fashioned usage of “bromide” derived from the early sleeping pills). And while it’s a cranky piece, it’s not wrong. Read More
  • Alzheimer's Disease

    A Missed Alzheimer’s Opportunity? Not So Much

    The Washington Post made quite a splash with this story about Pfizer, Enbrel (etanercept), and Alzheimer’s disease. There’s already been a lot of comment about it yesterday on Twitter and in some other venues, but I thought it might be useful to try to sum things up in an easily accessible place. Here we go: Read More
  • Cancer

    No Pain, and No Worries?

    The FAAH (fatty acid amide hydrolase) enzyme system has provided a number of headlines over the years. FAAH itself is involved in the brain’s endocannabinoid system – it clears neurotransmitters like anandamide – and a number of other biologically important hydroxyethylamide and acyltaurines. So the potential for inhibitors of it… Read More
  • Alzheimer's Disease

    A Brief Note About Alzheimer’s

    Well, there it is. Biogen and Eisai have announced just this morning that they’re halting Phase III trials of aducanumab, their anti-amyloid antibody, after the monitoring committee judged that further treatment would be futile. I’m not going to do some sort of victory dance, because (once again) this is bad news for Alzheimer’s… Read More
  • Cancer

    An Unexpected Halt in Multiple Myeloma for Venetoclax

      Venetoclax (ABT-199) is an unusual drug. But now there’s some unusually bad (and unexpected) news about it. That’s the structure at right, and medicinal chemists will understand immediately why it’s a bit of an outlier. With a molecular weight of 868, that structure just keeps on going, with a somefeatures that you donR… Read More
  • Business and Markets

    Zafgen: Will There Be a Third Act?

    A few years ago on this blog, I wrote several times about a small company called Zafgen and their unusual epoxide-based chemical matter (beloranib) that was in development for the rare Prader-Willi syndrome. That’s a genetic disorder that includes, among many other problems, constant hunger (with the complications that you’d expect fro… Read More
  • Business and Markets

    The Clinic Giveth And Most Definitely Taketh Away

    There have been some pretty dramatic clinical trial results coming out recently, and unfortunately drama is a variable that can take either a positive or a negative sign in front of it. On the plus side, MacroGenix, a company that not many people had been paying attention to, announced results of a head-to-head trial of… Read More
  • Biological News

    Precision Medicine Real Soon Now

    Here’s a strongly opinionated look at where the “precision medicine” field is these days, and I think that this is just the sort of article that the field (and the journalists covering it) need to see, whether you agree with it or not: In 1999 Francis Collins published a foundational document of precision medicine entitled… Read More
  • Alzheimer's Disease

    Another Alzheimer’s Antibody Fails. There Will Be More.

    To what should be absolutely no human being’s surprise, another amyloid-antibody trial has failed. Roche announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. They’re still going on with a study in familial early-onset disease in Colombia, and they ha… Read More
...234...